Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 4
2003 3
2004 4
2005 11
2006 5
2007 3
2008 3
2009 9
2010 5
2011 8
2012 8
2013 5
2014 3
2015 4
2016 7
2017 2
2018 2
2019 2
2020 1
2021 2
2022 2
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

89 results

Results by year

Filters applied: . Clear all
Page 1
Evofosfamide for the treatment of human papillomavirus-negative head and neck squamous cell carcinoma.
Jamieson SM, Tsai P, Kondratyev MK, Budhani P, Liu A, Senzer NN, Chiorean EG, Jalal SI, Nemunaitis JJ, Kee D, Shome A, Wong WW, Li D, Poonawala-Lohani N, Kakadia PM, Knowlton NS, Lynch CR, Hong CR, Lee TW, Grénman RA, Caporiccio L, McKee TD, Zaidi M, Butt S, Macann AM, McIvor NP, Chaplin JM, Hicks KO, Bohlander SK, Wouters BG, Hart CP, Print CG, Wilson WR, Curran MA, Hunter FW. Jamieson SM, et al. Among authors: senzer nn. JCI Insight. 2023 Feb 22;8(4):e169136. doi: 10.1172/jci.insight.169136. JCI Insight. 2023. PMID: 36810255 Free PMC article. No abstract available.
Corrigendum to "Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer" [Gynecologic Oncology Volume 161, Issue 3, June 2021, Pages 676-680].
Rocconi RP, Monk BJ, Walter A, Herzog TJ, Galanis E, Manning L, Bognar E, Wallraven G, Stanbery L, Aaron P, Senzer N, Coleman RL, Nemunaitis J. Rocconi RP, et al. Among authors: senzer n. Gynecol Oncol. 2023 Feb;169:173. doi: 10.1016/j.ygyno.2022.11.010. Epub 2022 Nov 28. Gynecol Oncol. 2023. PMID: 36456375 No abstract available.
ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer.
Rocconi RP, Stanbery L, Tang M, Walter A, Monk BJ, Herzog TJ, Coleman RL, Manning L, Wallraven G, Horvath S, Bognar E, Senzer N, Brun S, Nemunaitis J. Rocconi RP, et al. Among authors: senzer n. Commun Med (Lond). 2022 Aug 29;2:106. doi: 10.1038/s43856-022-00163-y. eCollection 2022. Commun Med (Lond). 2022. PMID: 36051466 Free PMC article.
Corrigendum to "Long-term follow-up of Phase 2A trial results involving advanced ovarian cancer patients treated with Vigil® in frontline maintenance" [Gynecol. Oncol. Rep. 34 (2020) 100648].
Oh J, Barve M, Senzer N, Aaron P, Manning L, Wallraven G, Bognar E, Stanbery L, Horvath S, Manley M, Nemunaitis J, Walter A, Rocconi RP. Oh J, et al. Among authors: senzer n. Gynecol Oncol Rep. 2021 Mar 1;36:100740. doi: 10.1016/j.gore.2021.100740. eCollection 2021 May. Gynecol Oncol Rep. 2021. PMID: 34095420 Free PMC article.
Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer.
Rocconi RP, Monk BJ, Walter A, Herzog TJ, Galanis E, Manning L, Bognar E, Wallraven G, Stanbery L, Aaron P, Senzer N, Coleman RL, Nemunaitis J. Rocconi RP, et al. Among authors: senzer n. Gynecol Oncol. 2021 Jun;161(3):676-680. doi: 10.1016/j.ygyno.2021.03.009. Epub 2021 Mar 11. Gynecol Oncol. 2021. PMID: 33715892 Clinical Trial.
Long-term follow-up of Phase 2A trial results involving advanced ovarian cancer patients treated with Vigil® in frontline maintenance.
Oh J, Barve M, Senzer N, Aaron P, Manning L, Wallraven G, Bognar E, Stanbery L, Horvath S, Manley M, Nemunaitis J, Walter A, Rocconi RP. Oh J, et al. Among authors: senzer n. Gynecol Oncol Rep. 2020 Sep 17;34:100648. doi: 10.1016/j.gore.2020.100648. eCollection 2020 Nov. Gynecol Oncol Rep. 2020. PMID: 33364285 Free PMC article. No abstract available.
Chimeric Antigen Receptor T-Cell Therapy: Reach to Solid Tumor Experience.
Metzinger MN, Verghese C, Hamouda DM, Lenhard A, Choucair K, Senzer N, Brunicardi FC, Dworkin L, Nemunaitis J. Metzinger MN, et al. Among authors: senzer n. Oncology. 2019;97(2):59-74. doi: 10.1159/000500488. Epub 2019 Jul 1. Oncology. 2019. PMID: 31261152 Review.
Evofosfamide for the treatment of human papillomavirus-negative head and neck squamous cell carcinoma.
Jamieson SM, Tsai P, Kondratyev MK, Budhani P, Liu A, Senzer NN, Chiorean EG, Jalal SI, Nemunaitis JJ, Kee D, Shome A, Wong WW, Li D, Poonawala-Lohani N, Kakadia PM, Knowlton NS, Lynch CR, Hong CR, Lee TW, Grénman RA, Caporiccio L, McKee TD, Zaidi M, Butt S, Macann AM, McIvor NP, Chaplin JM, Hicks KO, Bohlander SK, Wouters BG, Hart CP, Print CG, Wilson WR, Curran MA, Hunter FW. Jamieson SM, et al. Among authors: senzer nn. JCI Insight. 2018 Aug 23;3(16):e122204. doi: 10.1172/jci.insight.122204. eCollection 2018 Aug 23. JCI Insight. 2018. PMID: 30135316 Free PMC article. Clinical Trial.
89 results